Our findings also demonstrated that ccRCC patients in CXCL13+CXCR5+ group had a worse overall survival and disease free survival compared with patients in CXCL13−CXCR5− or CXCL13−CXCR5+/CXCL13+CXCR5− groups, indicating that CXCL13/CXCR5 axis might be a potential prognostic biomarker for ccRCC. The gene discussed is CXCR5; the disease is nonpapillary renal cell carcinoma.